Qingxin Lei

Title: Qingxin Lei: Innovator in Anti-Tumor Therapeutics

Introduction

Qingxin Lei is a notable inventor based in China, recognized for his contributions to the field of anti-tumor therapeutics. His innovative work focuses on developing conjugates that enhance the efficacy of cancer treatments. Despite having no patents registered under his name, his research has significant implications for cancer therapy.

Latest Patents

Qingxin Lei's latest patents include two significant inventions. The first is titled "Medicament For Treatment Of A Tumor Comprising A Endostatin And Polyethylene Glycol Conjugate." This invention discloses an anti-tumor conjugate and pharmaceutical compositions or kits that include the conjugate. It also outlines a method for producing the anti-tumor conjugate, which is metabolically stable in vivo and is ultimately available for tumor treatment and the production of anti-tumor medicaments. The second patent is "Arginine Deiminase Conjugate For The Treatment Of Tumors." This invention provides conjugates formed by coupling arginine deiminase and polyethylene glycol, which have arginine deiminase activity for use in preventing or treating cancer. It also includes a method for prolonging the in vivo half-life and anti-cancer efficacy of the arginine deiminase in the conjugate.

Career Highlights

Qingxin Lei has worked at prestigious institutions, including Tsinghua University and Protgen Ltd. His experience in these organizations has allowed him to contribute significantly to research in cancer treatment.

Collaborations

Some of his notable coworkers include Yongzhang Luo and Qing Han, who have collaborated with him on various research projects.

Conclusion

Qingxin Lei's innovative work in anti-tumor therapeutics showcases his commitment to advancing cancer treatment methodologies. His research has the potential to make a significant impact in the field of oncology.